Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons.
从 GalSafe 神经元开发组织工程神经肌肉接口。
基本信息
- 批准号:10385405
- 负责人:
- 金额:$ 25.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-15 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAfferent NeuronsAnimalsArchitectureAutologous TransplantationAxonAxotomyBiological AssayBiological ProductsBiomassBungarotoxinsCaliberCarbohydratesCell Differentiation processCell SurvivalCellsChronicClinicClinicalClinical TrialsControl GroupsCyclic GMPDefectDevelopmentDistalEmbryoEngineeringEnvironmentEnzyme-Linked Immunosorbent AssayFDA approvedFamily suidaeFunctional RegenerationGalactosidaseGenetic EngineeringHarvestHumanHydrogelsImmune responseImplantIn VitroInduced pluripotent stem cell derived neuronsInjectableInjuryLabelLaboratoriesLactate DehydrogenaseLesionLicensingMaintenanceMedicalModelingMotorMotor NeuronsMultiple TraumaMuscleMuscle CellsMuscle functionNatural regenerationNerveNervous system structureNeuromuscular JunctionNeuronsOperative Surgical ProceduresOrganOutcomePatientsPennsylvaniaPeripheral nerve injuryPhasePlayPopulationProcessProtocols documentationProxyQuality of lifeRattusRecoveryRecovery of FunctionRiskRodentSchwann CellsSensorySiteSmall Business Innovation Research GrantSourceSpinal CordStructureSynaptophysinTechniquesTestingTimeTissue EngineeringTissue TransplantationTissuesTraumaTumorigenicityUniversitiesaxon regenerationbiofabricationclinical practicedesignefficacy studyexperiencehuman stem cellsimmunocytochemistryimplantationin vivoin vivo evaluationinjury and repairlimb injurymanufacturing processmeetingsminimally invasivenerve damagenerve injurynerve repairnerve supplyneural networkneuromuscularperoneal nervephase 2 studyporcine modelpre-clinicalpreclinical safetypreservationproduct developmentprogramsregenerativereinnervationrepair strategyrepairedsafety studystandard of care
项目摘要
PROJECT SUMMARY
Major peripheral nerve injury (PNI) is classified as an injury with a long defect (≥3cm) or occurring proximally,
requiring long regenerative distances of the host nerve to distal structures (distal nerve, target muscle, etc.).
These features result in minimal, if any, functional regeneration as the distal nerve and muscle often degenerate
before the host nerve is able to reinnervate these structures due to inherently slow regeneration rates. Since
current standard clinical practices delay repairing nerve injuries until the patient (in cases of polytrauma) or the
injury site is stabilized, functional recovery is often extremely limited. In order to maintain the innervation
capability of nerves and muscles following injury, the team at Axonova Medical has developed a proxy for these
degenerating axons to maintain or “babysit” the distal structures until the host axons are able to reinnervate the
distal targets. This product, the tissue engineered neuromuscular interface (TE-NMI), consists of axon tracts
spanning a discrete population of neurons within a hydrogel column. Notably, the diameter of TE-NMIs is
designed to be on the scale of micrometers, making them easily injectable to facilitate incorporation into current
standard of care practices in the clinic. In pre-clinical rodent studies, TE-NMIs have been seen to extend axons
into distal structures post implantation, resulting in babysitting of distal nerve and muscle, therefore keeping it
receptive to eventual host axon reinnervation.
Previously, laboratory-grade TE-NMIs have been fabricated using primary rat and porcine neurons as well as
human induced pluripotent stem cell (iPSC)-derived neurons. In this study, a clinical product will be developed
and characterized using GalSafe® neurons as the starting biomass. GalSafe® tissue is an FDA-approved
xenogeneic source produced by Revivicor, Inc. Revivicor has genetically engineered swine to produce tissue
lacking a carbohydrate, known as -galactosidase, that is known to play a key role in eliciting an immune
response in humans. GalSafe® neurons are harvested from the spinal cords of GalSafe® swine embryo, and is
the chosen biomass for Axonova’s other product, tissue engineered nerve grafts (TENGs). For this proposal,
initial characterization and a preliminary in vivo study to determine the efficacy of TE-NMIs to promote recovery
in a chronic axotomy model in swine will be carried out. Successful execution of these studies will accelerate
preclinical safety and efficacy studies and will be incorporated in Axonova’s IND application. Overall, TE-NMIs
hold promise in transforming the field of nerve repair by significantly increasing the clinical window for PNI repair.
项目摘要
主要周围神经损伤(PNI)被分类为具有长缺损(≥3cm)或发生在近端的损伤,
需要宿主神经到远端结构(远端神经、目标肌肉等)的长再生距离。
这些特征导致最小的,如果有的话,功能性再生,因为远端神经和肌肉经常退化
在宿主神经能够重新支配这些结构之前,由于固有的缓慢再生速率。以来
目前的标准临床实践延迟了神经损伤的修复,直到患者(在多发性创伤的情况下)或
受伤部位稳定后,功能恢复往往极其有限。为了维持神经支配
由于神经和肌肉在受伤后的能力,Axonova Medical的团队已经开发了一种替代品,
退化的轴突以维持或“照看”远端结构,直到宿主轴突能够重新神经支配远端结构。
远端目标该产品,组织工程神经肌肉接口(TE-NMI),由轴突束
跨越水凝胶柱内离散的神经元群体。值得注意的是,TE-NMI的直径为
设计为微米级,使其易于注射,以促进纳入电流
临床护理实践标准。在临床前啮齿动物研究中,TE-NMIs已经被发现延伸轴突
植入后进入远端结构,导致远端神经和肌肉的保姆,因此保持其
接受最终的宿主轴突再神经支配。
以前,实验室级TE-NMI已经使用原代大鼠和猪神经元以及
人诱导多能干细胞(iPSC)衍生的神经元。本研究将开发一种临床产品
并使用GalSafe®神经元作为起始生物质进行表征。GalSafe®组织是FDA批准的
Revivicor,Inc.生产的异种源Revivicor已经对猪进行了基因工程改造,
缺乏一种称为β-半乳糖苷酶的碳水化合物,这种碳水化合物在引发免疫反应中起着关键作用。
人类的反应。GalSafe®神经元从GalSafe®猪胚胎的脊髓收获,并且
Axonova的另一种产品组织工程神经移植物(TENGs)的选择生物质。对于这一提议,
初步表征和初步体内研究,以确定TE-NMIs促进恢复的功效
在猪的慢性轴突切断模型中进行。这些研究的成功实施将加速
临床前安全性和有效性研究,并将纳入Axonova的IND申请。总体而言,
通过显著增加PNI修复的临床窗口,有望改变神经修复领域。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kritika Katiyar其他文献
Kritika Katiyar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kritika Katiyar', 18)}}的其他基金
Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons
利用 GalSafe 猪神经元生成组织工程神经移植物
- 批准号:
10473788 - 财政年份:2018
- 资助金额:
$ 25.04万 - 项目类别:
Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons
利用 GalSafe 猪神经元生成组织工程神经移植物
- 批准号:
10268167 - 财政年份:2018
- 资助金额:
$ 25.04万 - 项目类别:
Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons
利用 GalSafe 猪神经元生成组织工程神经移植物
- 批准号:
10011078 - 财政年份:2018
- 资助金额:
$ 25.04万 - 项目类别:
Mechanisms for Axonal Guidance Using Living Tissue Engineered Scaffolds
使用活组织工程支架进行轴突引导的机制
- 批准号:
9335678 - 财政年份:2015
- 资助金额:
$ 25.04万 - 项目类别:
Mechanisms for Axonal Guidance Using Living Tissue Engineered Scaffolds
使用活组织工程支架进行轴突引导的机制
- 批准号:
8983595 - 财政年份:2015
- 资助金额:
$ 25.04万 - 项目类别:
相似海外基金
How Spinal Afferent Neurons Control Appetite and Thirst
脊髓传入神经元如何控制食欲和口渴
- 批准号:
DP220100070 - 财政年份:2023
- 资助金额:
$ 25.04万 - 项目类别:
Discovery Projects
The mechanisms of the signal transduction from brown adipocytes to afferent neurons and its significance.
棕色脂肪细胞向传入神经元的信号转导机制及其意义。
- 批准号:
23K05594 - 财政年份:2023
- 资助金额:
$ 25.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Neurobiology of Intrinsic Primary Afferent Neurons
内在初级传入神经元的神经生物学
- 批准号:
10477437 - 财政年份:2021
- 资助金额:
$ 25.04万 - 项目类别:
GPR35 on Vagal Afferent Neurons as a Peripheral Drug Target for Treating Diet-Induced Obesity
迷走神经传入神经元上的 GPR35 作为治疗饮食引起的肥胖的外周药物靶点
- 批准号:
10315571 - 财政年份:2021
- 资助金额:
$ 25.04万 - 项目类别:
Neurobiology of Intrinsic Primary Afferent Neurons
内在初级传入神经元的神经生物学
- 批准号:
10680037 - 财政年份:2021
- 资助金额:
$ 25.04万 - 项目类别:
Neurobiology of Intrinsic Primary Afferent Neurons
内在初级传入神经元的神经生物学
- 批准号:
10654779 - 财政年份:2021
- 资助金额:
$ 25.04万 - 项目类别:
Neurobiology of Intrinsic Primary Afferent Neurons
内在初级传入神经元的神经生物学
- 批准号:
10275133 - 财政年份:2021
- 资助金额:
$ 25.04万 - 项目类别:
GPR35 on Vagal Afferent Neurons as a Peripheral Drug Target for Treating Diet-Induced Obesity
迷走神经传入神经元上的 GPR35 作为治疗饮食引起的肥胖的外周药物靶点
- 批准号:
10470747 - 财政年份:2021
- 资助金额:
$ 25.04万 - 项目类别:
Roles of mechanosensory ion channels in myenteric intrinsic primary afferent neurons
机械感觉离子通道在肌间固有初级传入神经元中的作用
- 批准号:
RGPIN-2014-05517 - 财政年份:2018
- 资助金额:
$ 25.04万 - 项目类别:
Discovery Grants Program - Individual
Roles of mechanosensory ion channels in myenteric intrinsic primary afferent neurons
机械感觉离子通道在肌间固有初级传入神经元中的作用
- 批准号:
RGPIN-2014-05517 - 财政年份:2017
- 资助金额:
$ 25.04万 - 项目类别:
Discovery Grants Program - Individual